Litigation Details for Walgreen Co. v. Gilead Sciences, Inc. (N.D. Cal. 2021)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2021-09-22
Court	District Court, N.D. California	Date Terminated
Cause	15:1 Antitrust Litigation	Assigned To
Jury Demand	Plaintiff	Referred To
Parties	BRISTOL-MYERS SQUIBB COMPANY
Patents	6,043,230; 6,639,071; 6,642,245; 6,703,396; 8,592,397; 8,716,264; 9,457,036
Attorneys	William Francis Murphy
Firms	Dillingham and Murphy, LLP
Link to Docket	External link to docket

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

The biologic drug covered by the patents cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-09-22	1	Complaint	5,977,089 (“the ‘089 Patent”), and 6,043,230 (“the ‘230 Patent”). These three 11 patents all derive from the… the TDF Patents (the 9 ‘695 patent, the ‘089 patent, the ‘230 patent, and the ‘946 patent), which …Gilead’s Viread patent portfolio consists of U.S. Patents Nos. 5,922,695 (“the 10 ‘695 Patent”), 5,977,089… (“the ‘245 patent”) and 6,703,396 (“the ‘396 patent”) 8 (collectively “the FTC Patents”). Truvada … invalid. 18 These patents include U.S. Patent Nos. 8,592,397 (“the ‘397 patent”), 8,716,264 (“the ‘	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document